Latest Breaking News On - Michael castagna - Page 1 : vimarsana.com

MannKind (MNKD) Q1 2024 Earnings Call Transcript

MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical ...

MannKind Corporation (NASDAQ:MNKD) Q1 2024 Earnings Call Transcript

Clofazimine Inhalation Suspension Fast Tracked for NTM Lung Disease

Clofazimine is an antibiotic that inhibits mycobacterial growth and binds preferentially to mycobacterial DNA.

MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease

MannKind Repays Certain Debt Obligations

Credit and security agreement with MidCap Financial Trust repaid in full for approximately $31.6 millionConvertible note issued to Mann Group LLC repaid in exchange for 1.5 million shares of common...

MannKind Announces CFO Transition

MannKind Announces CFO Transition

Steven B. Binder announces planned retirement and is appointed Executive Vice President, Special Projects, effective April 22, 2024, through Decem...

MannKind caps off record year with Q4 earnings beat | Pacific Coast Business Times

MannKind employees including CEO Michael Castagna, center, ring the opening bell of the Nasdaq on May 23. (courtesy photo) Westlake Village-based MannKind Corporation capped off a record year with a fourth quarter to remember, beating analysts' estimates and setting up for a brighter future. MannKind, a biotechnology company that develops treatments for diabetes and pulmonary

Wedbush Weighs in on MannKind Co.'s Q2 2024 Earnings (NASDAQ:MNKD)

MannKind Co. (NASDAQ:MNKD – Free Report) – Analysts at Wedbush issued their Q2 2024 earnings estimates for shares of MannKind in a research report issued to clients and investors on Wednesday, February 28th. Wedbush analyst A. Argyrides forecasts that the biopharmaceutical company will post earnings of $0.02 per share for the quarter. Wedbush currently has […]